QuantaMatrix Inc (317690) Fair Value & Analysis
Healthcare · KR · Market cap 57.5B KRW
Fair value as of: Jul 9, 2026
From 1 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from 9,196 KRW to 1,812 KRW (−80.3%) since Jun 24, 2026. Share price −16.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,405 KRW – 5,981 KRW · fair‑value band 1,196 KRW – 2,266 KRW · the 2,405 KRW price screens above the 1,812 KRW fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
QuantaMatrix Inc (317690) currently trades at 2,405 KRW, while our model-based Fair Value estimate is 1,812 KRW — implying the stock looks roughly 24.6% overvalued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 3.4B KRW. Revenue declined 28.7% year over year. It earns a return on equity of -85.8%. Net debt stands at 9.3B KRW. Fundamentals as of Jul 9, 2026
Our scenario range runs from 1,196 KRW (bear case) to 2,266 KRW (bull case); at 2,405 KRW, the current price sits above that range. The share trades about 63% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside — at -25%, 317690 screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
QuantaMatrix Inc reported revenue of 3.7B KRW in FY2025 versus 550M KRW in FY2021, a compound +60.9%/yr. Reported net income was −19.5B KRW in FY2025.
Is 317690 fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is QuantaMatrix Inc (317690) undervalued?
What is the fair value of 317690?
What is the quality score of 317690?
What is the revenue of QuantaMatrix Inc (317690)?
What is the net profit margin of 317690?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.